TY - JOUR U1 - Zeitschriftenartikel, wissenschaftlich - begutachtet (reviewed) A1 - Stephan, David A1 - Weiher, Hans A1 - Schmidt-Wolf, Ingo G. H. T1 - CIK Cells and HDAC Inhibitors in Multiple Myeloma JF - International Journal of Molecular Sciences N2 - Multiple myeloma is the second most common hematological malignancy. Despite all the progress made in treating multiple myeloma, it still remains an incurable disease. Patients are left with a median survival of 4-5 years. The combined treatment of multiple myeloma with histone deacetylase inhibitors and cytokine-induced killer cells provides a promising targeted treatment option for patients. This study investigated the impact of a combined treatment compared to treatment with histone deacetylase inhibitors. The experiments revealed that a treatment with histone deacetylase (HDAC) inhibitors could reduce cell viability to 59% for KMS 18 cell line and 46% for the U-266 cell line. The combined treatment led to a decrease of cell viability to 33% for KMS 18 and 27% for the U-266 cell line, thus showing a significantly better efficacy than the single treatment. KW - multiple myeloma KW - cytokine-induced killer cells KW - CIK cells KW - histone deacetylase inhibitors KW - immunotherapy KW - cancer treatment UN - https://nbn-resolving.org/urn:nbn:de:hbz:1044-opus-30480 SN - 1422-0067 SS - 1422-0067 U6 - https://doi.org/10.3390/ijms18050945 DO - https://doi.org/10.3390/ijms18050945 PM - 28468247 VL - 18 IS - 5 PB - MDPI CY - Basel ER -